Skip to main content

Table 1 Selected patient and tumor characteristics

From: Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials

 

N = 1031

Age in years

 

  Median (range)

52.5 (22–79)

Number of positive nodes

 

  Median (range)

4 (0–43)

 

N (%)

Randomization group

 

  E-T-CMF

504 (48.9)

  E-CMF

157 (15.2)

  ET-CMF

370 (35.9)

Age

 

  <50

426 (41.3)

  ≥50

605 (58.7)

Menopausal status

 

  Premenopausal

484 (46.9)

  Postmenopausal

547 (53.1)

Type of surgery

 

  MRM

706 (68.5)

Breast-conserving

325 (31.5)

Tumor size (cm)

 

  ≤2

320 (31.0)

  2.1-5

584 (56.6)

  >5

127 (12.3)

Number of positive nodes

 

  0-3

408 (39.6)

  ≥4

623 (60.4)

Histological grade

 

  I-II

513 (49.8)

  III-Undifferentiated

518 (50.2)

Histology type

 

  Ductal

800 (77.6)

  Lobular

105 (10.2)

  Mixed

73 (7.1)

  Other

53 (5.1)

Radiotherapy

782 (75.8)

Hormonal therapy

799 (77.5)

  1. MRM, modified radical mastectomy; N, number.